By Cecilia Butini

Sanofi SA said Wednesday that a Phase 3 study of a drug to treat hereditary condition Hemophilia A has met its primary and secondary endpoints.

The French pharmaceutical company said the drug, which is called efanesoctocog alfa, has shown meaningful prevention of bleeding episodes in people who have received the treatment once a week.

It also proved to be superior to previously-used therapies.

In people affected by hemophilia, blood doesn't clot properly, leading to abnormal bleeding.

The study was conducted together with Swedish Orphan Biovitrum AB, also known as Sobi.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

March 09, 2022 01:32 ET (06:32 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Giu 2024 a Lug 2024 Clicca qui per i Grafici di Sanofi
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Lug 2023 a Lug 2024 Clicca qui per i Grafici di Sanofi